Shanlee M Davis, Susan Howell, Jennifer Janusz, Najiba Lahlou, Regina Reynolds, Talia Thompson, Karli Swenson, Rebecca Wilson, Judith L Ross, Philip S Zeitler, Nicole R Tartaglia
{"title":"Testosterone Effects on Short-Term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants with 47,XXY.","authors":"Shanlee M Davis, Susan Howell, Jennifer Janusz, Najiba Lahlou, Regina Reynolds, Talia Thompson, Karli Swenson, Rebecca Wilson, Judith L Ross, Philip S Zeitler, Nicole R Tartaglia","doi":"10.1210/clinem/dgaf217","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the mini-puberty period of infancy.</p><p><strong>Objective: </strong>We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.</p><p><strong>Design: </strong>Double-blind randomized controlled trial, 2017-2021.</p><p><strong>Setting: </strong>US tertiary care pediatric hospital.</p><p><strong>Patients: </strong>Infants 30-90 days of age with prenatally identified, non-mosaic 47,XXY (n=71).</p><p><strong>Intervention: </strong>Testosterone cypionate 25mg intramuscular injections every 4 weeks for 3 doses.</p><p><strong>Main outcome measures: </strong>The a priori primary outcomes were change in percent fat mass (%FM) z-scores and change in the total composite percentile on Alberta Infant Motor Scales (AIMS) assessment from baseline to 12 weeks.</p><p><strong>Results: </strong>The between group difference in change in %FM z-scores was -0.57 [95% CI -1.1, -0.06], p=0.03), secondary to greater increases in lean mass in the testosterone-treated group (1.5±0.4 kg vs 1.2±0.4, p=0.001). Testosterone suppressed gonadotropins and inhibin B (p<0.001 for all). In contrast, there were no significant group differences in short term motor, cognitive, or language outcomes (p>0.15 for all).</p><p><strong>Conclusions: </strong>In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure, however this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY, however long term follow up on physical health, neurodevelopment and testicular function is needed.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf217","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景:47,XXY/Klinefelter 综合征(XXY)与睾丸功能受损以及身体发育、新陈代谢和神经发育差异有关。XXY的临床特征可能会受到婴儿小青春期睾酮的影响:我们检验了外源性睾酮治疗会对XXY婴儿的短期身体、激素和神经发育结果产生积极影响这一假设:双盲随机对照试验,2017-2021年.Setting:美国三级儿科医院:干预措施:环丙酸睾丸素25(睾酮)、睾酮25(睾酮)、睾酮25(睾酮)、睾酮25(睾酮)、睾酮25(睾酮)、睾酮25(睾酮):干预措施:环丙酸睾酮 25 毫克肌肉注射,每 4 周一次,共注射 3 次:先验的主要结果是脂肪量百分比(%FM)z-分数的变化和阿尔伯塔婴儿运动量表(AIMS)评估总综合百分位数从基线到12周的变化:睾酮治疗组婴儿的瘦体重增加较多(1.5±0.4 kg vs 1.2±0.4,p=0.001),这是因为睾酮治疗组婴儿的瘦体重增加较多(1.5±0.4 kg vs 1.2±0.4,p=0.001)。睾酮抑制了促性腺激素和抑制素 B(均为 p0.15):结论:在这项针对XXY婴儿的双盲随机对照试验中,睾酮注射会导致全身雄激素暴露引起的身体影响,但该剂量会抑制下丘脑-垂体-性腺轴。神经发育结果并未受到治疗的影响。这些结果并不支持对患有 XXY 的婴儿进行常规睾酮治疗,但需要对婴儿的身体健康、神经发育和睾丸功能进行长期随访。
Testosterone Effects on Short-Term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants with 47,XXY.
Context: 47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the mini-puberty period of infancy.
Objective: We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.
Patients: Infants 30-90 days of age with prenatally identified, non-mosaic 47,XXY (n=71).
Intervention: Testosterone cypionate 25mg intramuscular injections every 4 weeks for 3 doses.
Main outcome measures: The a priori primary outcomes were change in percent fat mass (%FM) z-scores and change in the total composite percentile on Alberta Infant Motor Scales (AIMS) assessment from baseline to 12 weeks.
Results: The between group difference in change in %FM z-scores was -0.57 [95% CI -1.1, -0.06], p=0.03), secondary to greater increases in lean mass in the testosterone-treated group (1.5±0.4 kg vs 1.2±0.4, p=0.001). Testosterone suppressed gonadotropins and inhibin B (p<0.001 for all). In contrast, there were no significant group differences in short term motor, cognitive, or language outcomes (p>0.15 for all).
Conclusions: In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure, however this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY, however long term follow up on physical health, neurodevelopment and testicular function is needed.
期刊介绍:
The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.